The independent source for health policy research, polling, and news.
1-20 of 172 results
The rapid emergence of the Chinese biotech industry has panicked U.S. politicians, but investors and patients caution that a clampdown on pharmaceutical collaboration could hurt everyone.
Health workers are continuing to treat patients and train caregivers in the Democratic Republic of Congo, where the second-deadliest Ebola outbreak on record continues.
From screwworm to flesh-eating bacteria, mounting public health risks are emerging in the wake of deep cuts to federal health agencies and programs.
Travel bans and conflict have disrupted supply chains in the Democratic Republic of Congo, leaving health workers without Ebola tests and protective gear needed to contain the outbreak.
Infectious disease specialists say the viruses are unlikely to become pandemics, but some are still raising concerns about the federal health response and what it portends should a pandemic similar to or worse than covid occur.
Some of the Trump administration’s dramatic funding and policy shifts are facing major pushback for the first time — not from Congress, but from the courts. Federal judges around the country are attempting to pump the brakes on efforts to freeze government spending, shut down the U.S. Agency for International Development, eliminate access to health-related webpages and datasets, and limit grant funding provided by the National Institutes of Health. Meanwhile, Congress is off to a slow start in trying to turn President Donald Trump’s agenda into legislation, although Medicaid is clearly high on the list for potential funding cuts. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Maya Goldman of Axios News join KFF Health News’ Julie Rovner to discuss these topics and more. Also this week, Rovner interviews Mark McClellan, director of the Duke-Margolis Institute for Health Policy and a former health official during the George W. Bush administration, about the impact of cutting funding to research universities.
By withdrawing from the World Health Organization and overhauling aid, Trump’s new executive orders endanger Americans and the globe, researchers warn. The move also cedes U.S. power to other nations.
The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of “An Arm and a Leg,” hear how a decades-long global fight to reform drug patents is helping to lower the cost.
The effort to end Guinea worm disease relies almost entirely on changes in people’s behavior. There is no cure, no vaccination. When the 39th president of the United States left office, Jimmy Carter campaigned to eradicate the disease.
Although the disease is currently spreading almost exclusively among men who have sex with men, some cases are turning up in other populations — and that number is likely to grow if public health officials don’t effectively nip the outbreak in the bud.
Public health officials say monkeypox is not as dangerous as covid and can be handled well with current treatments and if those at risk use caution. But the rollout of vaccines has been slow and led to angst among some at-risk people.
For now, monkeypox poses a low risk to the U.S. public, but it could become a problem if the spread is left unchecked. Here’s what everyone should know about it.
Covid cases are again climbing, but you wouldn’t know it from the behavior of public health and elected officials, much less the general public, all of whom seem to want to put the pandemic in the rearview mirror. Meanwhile, the fallout over the leaked Supreme Court draft opinion on abortion continues even as the Senate fails — again — to muster the votes to write abortion rights into law. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
The part of my London visit that I didn’t plan was testing positive for the coronavirus. I couldn’t get back to the U.S., but the U.K. didn’t care what I did or where I went.
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
As hospitals juggle holiday covid surges and all their other patients, the global supply chain crisis has left them short of critical supplies.
This new variant has set off alarm bells in the public health community, but much remains to be learned about it.
Covid is back with a vengeance, with some people clamoring for booster shots while others harden their resistance to getting vaccinated at all. Meanwhile, the Food and Drug Administration is pushing hard on drugmaker Pfizer’s request to upgrade the emergency authorization for its vaccine and give it final approval. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite health policy stories of the week they think you should read, too.
Scientists are trying to piece together why the delta variant so readily infects unvaccinated Americans, spewing 1,000 times more virus particles.
© 2026 KFF